| Next 10 |
Ad
MTSR News and Press Metsera Inc.
News | Metsera Inc. (NASDAQ:MTSR)
-
2025-06-14 08:46:43 ET More on Eli Lilly Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will Targeting The NaV1.8 Pathway In Pain Man...
-
2025-06-12 10:03:30 ET ... Read the full article on Seeking Alpha For further details see: Promising Results Of Amylin Analogs In Obesity: Metsera Case Review
-
2025-06-10 14:47:23 ET More on Metsera Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise Metsera GAAP EPS of -$1.03 misses by $0.28 Viking among notable gainers as Pfizer raises deal prospects Historical earnings data for Metsera F...
-
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Ch...
-
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call...
-
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog ...
-
2025-05-20 06:49:58 ET Summary VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain thousands of patients, a readout isn't a near-term pr...
-
2025-05-16 16:24:43 ET Summary Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival current market leaders if clinical data proves best-in-...
-
2025-05-13 10:28:18 ET More on Metsera Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation Viking among notable gainers as Pfizer raises deal prospects Why did Lilly...
-
Metsera Inc. (MTSR) is expected to report for Q1 2025
Stock Information
Get MTSR Alerts
News, Short Squeeze, Breakout and More Instantly...
Metsera Inc. Company Name:
MTSR Stock Symbol:
NASDAQ Market:
2.12% G/L:
$25.38 Last:
1,128,398 Volume:
$26.30 Open:
$25.38 Close:
Metsera Inc. Website:
Ad
-
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Ch...
-
Metsera Inc. (MTSR) is expected to report for Q1 2025
-
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chi...